Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults

Anterior Cruciate Ligament Reconstruction Clinical Trial

Official title:

Nutritional Intervention to Enhance Recovery After Arthroscopic Knee Surgery in Adults: A Randomized Controlled Feasibility Pilot Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06233825
• Other study ID #: 6038901
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2024
• Est. completion date: August 1, 2025

Study information

• Verified date: February 2024
• Source: Queen's University
• Contact: Chris McGlory, PhD
• Phone: 6135336000
• Email: chris.mcglory[@]queensu.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Loss of skeletal muscle mass (atrophy) and strength in the lower limb are consequences of elective knee surgery as result of prolonged disuse from limb immobilization and impaired mobility, as well as pathophysiological trauma. The highest rates of skeletal muscle mass and strength loss occur during the 2-week post-surgery period, considered the early phase of outpatient recovery. Alternative to resistance exercise and pharmacology, nutritional intervention represents one strategy to combat skeletal muscle disuse atrophy. Essential amino acids (EAA) and omega-3 fatty acids are known to independently potentiate rates of skeletal muscle protein synthesis and attenuate skeletal muscle atrophy in humans. However, the combined actions these nutritional strategies on skeletal muscle have not been explored in a pathophysiological context, such as surgery. With the ultimate goal to test the efficacy of the combined nutritional strategy to attenuate skeletal muscle disuse atrophy in the future, the aim of this present pilot study is to explore the feasibility of recruitment and retention of anterior cruciate ligament reconstruction (ACLR) outpatients from a single centre across 18 months for a 6-week nutritional intervention. Participants will consume either an intervention of omega-3 fatty acids and EAAs, or a placebo control of safflower oil and non-essential amino acids (NEAA), for 4 weeks before and 2 weeks after elective ACLR surgery. Furthermore, this pilot will characterize secondary outcomes of skeletal muscle mass, strength, and power, and integrated rates of muscle protein synthesis, as well as report participant adherence to protocols and incidence of adverse events.

Description:

Over their lifespan, many individuals experience episodes of skeletal muscle-disuse due to illness, injury, or elective surgery. Periods of prolonged skeletal muscle disuse, such after ACLR, result in the loss of skeletal muscle mass (atrophy) and strength. Skeletal muscle disuse precipitates several metabolic and functional impairments. Importantly, as the Canadian health care system shifts towards day surgeries and outpatient settings as opposed to in-hospital care, the development of patient-led strategies to mitigate skeletal muscle disuse atrophy has become increasingly vital. For most ACLR outpatients, resistance exercise is not feasible in the immediate 2-week post-surgical period, during which the rates of skeletal muscle mass and strength loss are highest. Outside of pharmacology, nutrition represents one alternative strategy to combat skeletal muscle-disuse atrophy during this time. Previous work reported that daily supplementation with EAA prior to and after total knee arthroplasty surgery attenuated skeletal muscle atrophy and enhanced recovery of functional mobility in adults. Similarly, chronic daily supplementation with omega-3 fatty acids reduced declines in quadriceps volume in healthy, young women during single-leg immobilization. This finding complemented previous work in which supplementation with omega-3 fatty acids potentiated muscle protein synthesis rates in response to an hyperaminoacidemic-hyperinsulinemic clamp, but not fasting rates in healthy younger, middle-aged, and older adults, while it additionally improved skeletal muscle strength and power. Together, these data suggest that combined intake of omega-3 fatty acids and EAAs may be an effective strategy to combat skeletal muscle-disuse atrophy, and perhaps loss of skeletal muscle strength, in response to ACLR. Whilst there is a growing body of literature to promote EAA and omega-3 fatty acids as anabolic stimuli, no work has explored the combined effect of these nutritional strategies in the pathophysiological context of surgery. Nutritional strategies represent an accessible treatment for skeletal muscle disuse atrophy that is independent of patient age, mobility, or current health status, which could prove favourable for surgical outpatients, as well as individuals experiencing periods of prolonged immobilization or bed rest. The future goal of this design is to test efficacy of the combined nutritional strategy of daily omega-3 fatty acid and EAA supplementation to attenuate of skeletal muscle disuse atrophy following elective knee surgery. However, the aim of the present randomized controlled pilot trial is to explore the feasibility of recruitment and retention of adult ACLR outpatients from a single centre across 18 months for a protocol that prescribes combination omega-3 fatty acid and EAA supplementation vs. a calorie- and nitrogen-matched placebo control supplement 4 weeks before and 2 weeks after ACLR surgery. This pilot will also characterize measurements of skeletal muscle volume, strength, and function, and integrated rates of skeletal muscle protein synthesis, as well as report participant adherence to protocols and the incidence of adverse events. The investigators envisage that the data generated from this trial will be used to inform the future large scale randomized controlled trial (RCT) that will examine the effect of the combined nutritional intervention on skeletal muscle volume and functional outcomes in response to ACLR. The results of future work may inform clinical practice and outpatient care guidelines to minimize loss of skeletal muscle mass and strength in response to elective surgery.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: August 1, 2025
• Est. primary completion date: August 1, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed anterior cruciate ligament injury requiring reconstruction surgery
• Surgery in Kingston, ON
• Patellar tendon graft or quadriceps tendon graft reconstruction procedure

Exclusion Criteria:

• Any muscular, neurological, respiratory, or metabolic disease, subject to investigators' discernment, would negatively affect the subject's ability to comply with the study requirements
• Any form of cancer currently or in the last 5 years
• Bleeding disorders or antiplatelet / anticoagulation therapy
• Currently taking fish oils or within the last 6 months
• Regular consumption (= 2x week) of fish oil or oily fish in the last 6 months
• Allergy or sensitivity to fish, shellfish or safflower oils
• Currently taking any form of steroid or within the last 6 months
• Medical inability to attain magnetic resonance imaging scans
• Known irregular responses to physical activity (e.g., shortness of breath, chest pain, dizziness, etc.)
• Surgery scheduled outside of research centre
• Scheduled surgery date < 5 weeks away
• Pregnant or plans to become pregnant within the next 6 months
• Any current illness that impacts ability to participate in protocols

Related Conditions & MeSH terms

• Anterior Cruciate Ligament Reconstruction
• Muscular Atrophy

Intervention

Dietary Supplement:
• Omega-3 Fatty Acids and Essential Amino Acids
Oil consumed as capsules. EAA come as powder to be mixed with water before drinking. 4 g of leucine per EAA dose.
• Safflower Oil and Non-Essential Amino Acids
Oil consumed as capsules. NEAA are isonitrogenous to intervention condition. Both supplement types are isoenergetic to intervention. NEAA come as powder to be mixed with water before drinking.

Locations

Country	Name	City	State
Canada	Queen's University	Kingston	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Dr. Chris McGlory, PhD

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of Recruitment and Retention	Number of participants recruited and retained. Criteria for success is 30 outpatients recruited and at least 22 retained.	18 months and 12 weeks (8 weeks post surgery), respectively.
Secondary	Muscle Mass	Change in quadriceps muscle mass measured by magnetic resonance imaging scan.	0 and 2 weeks
Secondary	Muscle Cross-Sectional Area	Change in quadriceps muscle cross sectional area measured by magnetic resonance imaging scan.	0 and 2 weeks
Secondary	Muscle Protein Synthesis	Muscle protein synthesis measured as fractional synthesis rate using combined protocol of skeletal muscle biopsy, stable isotope tracing, cavity ring down spectroscopy with liquid isotope analysis, and gas-chromatography pyrolysis isotope-ratio mass spectrometry.	-1 to 0 weeks and 0 to 2 weeks.
Secondary	Skeletal Muscle Phospholipid Composition	Phospholipid composition will be assessed by gas chromatography.	-4 and 2 weeks.
Secondary	Erythrocyte Phospholipid Composition	Phospholipid composition will be assessed by gas chromatography.	-4 and 2 weeks.
Secondary	Plasma Proteomics	Change in target signal intensity and protein concentration measured through proteome profiling by aptamer based SOMAscan assay.	-4, 0 and 2 weeks.
Secondary	Expression of Translational Factors Related to Skeletal Muscle Protein Synthesis	Activation of translational factors involved in skeletal muscle protein synthesis assessed by western blotting.	-4, 0 and 2 weeks.
Secondary	Muscle Function	Stair climb power test performance.	-4 and 8 weeks.
Secondary	Muscle Strength	Knee-extensor peak torque measured by dynamometry.	-4 and 8 weeks.
Secondary	Muscle Power	Isotonic power measured by dynamometry.	-4 and 8 weeks.
Secondary	Physical Activity	Non-sedentary time collected by accelerometer pre and post surgery.	-1 to 0 weeks and 0 to 2 weeks.
Secondary	Step Count	Average daily step count collected by accelerometer pre and post surgery.	-1 to 0 weeks and 0 to 2 weeks.